Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

36

Revenue 2017

Xtandi

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Xtandi was produced by Astellas.

Daily Brief

Daily Brief As an example, the algorithm recommends a price of $3, 094 for each course of Pfizer’s prostate cancer drug Xtandi – much lower than the current UK list price (almost 12

EMA starts review of Xtandi in non-metastatic prostate cancer

EMA starts review of Xtandi in non-metastatic prostate cancer So, if approved the new indication would move Xtandi up the treatment chain and could allow it to be used in more patients. ... Erleada is the first to claim approval, but Xtandi benefits from longstanding familiarity in CRPC treatment.

J&J’s Erleada first US drug for non-metastatic prostate cancer

J&J’s Erleada first US drug for non-metastatic prostate cancer It also gives J&J a leg-up in what looks set to be a big market tussle with Pfizer and Astellas and their Xtandi (enzalutamide) product, which has also been

PROSPER data reveal big Xtandi benefit in early-stage prostate cancer

PROSPER data reveal big Xtandi benefit in early-stage prostate cancer use of Xtandi to include men with early-stage prostate cancer that hasn’t spread to other areas of the body. ... responds to hormone therapy and, if approved, the new indication would move Xtandi up the treatment chain and could allow it to be used in

Dendreon appoints new R&D lead

Dendreon appoints new R&D lead Joining from Astellas Pharma, Dr Brown most recently served as senior medical director of oncology, where he led US medical strategy for the prostate cancer drug Xtandi (enzalutamide).

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...
MIT reveals new pill to deliver insulin
A new MIT research project, sponsored by Novo Nordisk, is aiming to deliver insulin orally with a pill that releases medicine in the stomach lining. Dina Patel interviews the team...
Fearless Girl cover
25 Women Leaders in UK Healthcare
Women trailblazers helping to shape the future of healthcare (Part 1)...

Infographics